A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer
Study of Ablation in Breast Cancer Patients
Sponsor: NRG Oncology
Enrolling: Male and Female Patients
IRB Number: AAAR2611
U.S. Govt. ID: NCT02364557
Contact: Eileen Connolly MD: 212-305-5050 / epc2116@cumc.columbia.edu
Additional Study Information: The purpose of the study is to determine whether ablation, which is the removal or destruction of a tumor (through SBRT and/or surgical resection of all known metastases) in oligometastatic breast cancer patients improves progression-free survival (PFS) and overall survival (OS).
This study is closed
Investigator
Eileen Connolly, MD, PhD
Do You Qualify?
Are you 18 years or older? Yes No
Do you have metastatic breast cancer? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Eileen Connolly MD
epc2116@cumc.columbia.edu
212-305-5050
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE